Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH) from a sell rating to a hold rating in a research report released on Friday.

Other analysts have also issued research reports about the stock. Craig Hallum began coverage on shares of Delcath Systems in a research report on Friday, June 28th. They set a buy rating and a $18.00 target price on the stock. HC Wainwright reaffirmed a buy rating and set a $22.00 price target on shares of Delcath Systems in a research note on Tuesday, August 6th. Finally, Stephens restated an overweight rating and set a $25.00 price objective on shares of Delcath Systems in a report on Tuesday, August 6th.

Delcath Systems Trading Down 1.1 %

NASDAQ:DCTH opened at $9.03 on Friday. The firm has a market cap of $250.91 million, a P/E ratio of -3.41 and a beta of 0.78. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $11.74. The stock’s 50 day simple moving average is $8.93 and its 200-day simple moving average is $7.32.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The company had revenue of $7.77 million for the quarter, compared to analysts’ expectations of $5.00 million. During the same period in the prior year, the firm posted ($0.58) EPS. Research analysts forecast that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Trading of Delcath Systems

Large investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC purchased a new stake in shares of Delcath Systems in the fourth quarter worth about $962,000. Vanguard Group Inc. boosted its holdings in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after acquiring an additional 161,678 shares during the period. BVF Inc. IL grew its position in Delcath Systems by 23.1% in the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after acquiring an additional 225,918 shares in the last quarter. Levin Capital Strategies L.P. grew its position in Delcath Systems by 12.2% in the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after acquiring an additional 5,969 shares in the last quarter. Finally, Rosalind Advisors Inc. raised its stake in shares of Delcath Systems by 155.1% during the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock valued at $22,184,000 after purchasing an additional 1,611,561 shares during the period. 61.12% of the stock is currently owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.